Substance P in Long-Lasting Asthma. Immunoinflammatory pathways by Todo-Bom, Ana et al.
Allergy Clin Immunol Int – J World Allergy Org, 18/5 (2006)
Research Trends 1
Background: Substance P (SP) was described at the begin-
ning of the 20th Century, and its biological action was recog-
nized to have implications in neurogenic inflammation and
constriction of smooth muscles. The changes associated with
inflammatory chronicity can compromise organ function re-
versibility. The role of neuromechanisms in the pathology of
the disease has been investigated in order to achieve better di-
agnosis and therapeutic approaches. The stimulation of
human cells, such as macrophages and polymorphonuclear
cells by SP leads to their activation and to the release of reac-
tive oxygen species (ROS) by these cells. Consequently, a
continuous inflammatory disability is observed, mainly if a
decrease in antioxidant defence occurs. SP is a substrate for
dipeptidyl peptidase IV (DPPIV), which is a multifunctional
molecule with enzymatic and proinflammatory activities.
CD26 is considered an activation T cell marker. The aim of
the present study was to analyse if serum SP values in long-
lasting asthma patients were related to lung function parame-
ters. It was also decided to analyze the relationship of SP with
superoxide dismutase (SOD) and total antioxidant activity in
serum (TAS), as well as its association to CD26/DPPIV val-
ues considering their immunological and inflammatory prop-
erties.
Methods/Data base: A group of individuals older than 65
years, including 64 asthmatic patients (mean age 72±5 years)
and 41 healthy individuals (mean age 79±7years) was select-
ed. Both subgroups were submitted to clinical observation, to
skin prick tests (SPT) and to SP, TAS, SOD, and DPPIV de-
terminations. T cell CD26 typing was also performed. Lung
function tests were done on all patients.
Results: Among the patients studied, 42 had positive skin
tests, mainly to house dust mites. Asthmatic patients showed a
significant increase in SP values (116.2±138.9 vs 39.5±17.9
pg/ml) when compared to controls and a significant decrease
in TAS levels (.85±.13 vs .91±.10 mM) and in SOD levels
(588.1±156.l vs 822.9±179.5 U/gHb). All patients were clini-
cally stable and presented an average percentage of predict
forced expiratory volume in the first second (FEV1) of
73.6±25.3 and median expiratory flow percentage of predict
(MEF50) of 38.8±26.7. DPPIV values were significantly in-
creased in asthmatics compared to controls (69.7±15.2 vs
58.6±14.3 U/L). The CD26 expression was only slightly in-
creased in asthmatic patients (41.9±10.2 vs 39.4±11.4). 
Conclusion: These results confirm the role of SP in asthma
and give a contribution for a better knowledge of the im-
munoinflammatory pathway associated with this chronic dis-
order. A final goal for these studies would be to achieve a bet-
ter therapeutic approach in order to improve the outcome of
asthmatic patients. 
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Introduction 
Substance P (SP) was named by Gaddum and Schild, at the
beginning of the 20th century, referring to the powder extracted
from equine tissues, which had potent hypotensive and contrac-
tile properties. Later it was introduced as part of the
tachykinins family, just as neurokinin A (NKA) and neurokinin
B (NKB), which share the same carboxyl terminal sequence
[1]. The biological actions of substance P are mediated by
tachykinin receptors, which belong to rhodopsin-like mem-
brane structures. There are three types of tachykinin receptors
exhibiting substance P preferences for NK1 [1]. Some of the
most considerable effects produced by substance P and other
tachykinins released from peripheral endings of primary senso-
ry neurons are collectively referred to as “neurogenic inflam-
mation.” Responses produced at the peripheral level by sensory
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neuropeptides are prominent on the vasculature but additional
tissue-specific responses such as bronchoconstriction have
been recognized.
Asthma is a chronic inflammatory disorder of the airways,
characterized by a widespread but variable bronchial obstruc-
tion and by hyperresponsiveness to several triggers [2]. The lim-
itation to the airflow described depends on the addictive effect
of the localized inflammatory process and on the smooth mus-
cle contraction, which in part results from the tachykinin action.
Asthmatic patients tend to develop a progressive decline in pul-
monary function that is correlated with age, sex, duration and
severity of the disease [3]. 
Lung function studies have demonstrated that the elderly
population with long-lasting asthma presents increased basal
airway narrowing and decreased bronchial reversibility more
considerable than in older individuals with late onset asthma
and disease evolution < 10 years [4, 5]. This respiratory func-
tion pattern can be even more severe as a consequence of the
immunoinflammatory changes associated with the ageing
process [6].
Recent studies with substance P antagonists have demon-
strated that SP has various proinflammatory and spasmogenic
effects both in asthma and in chronic bronchitis [1]. SP causes
degranulation of mast cells through direct activation of plasma
membrane G proteins mediating nonatopic hypersensitivity re-
actions [7]. SP can stimulate hematopoiesis and inflammatory
leukocytosis. Lymphocytes, macrophages, and mast cells have
SP receptors and can be stimulated to produce cytokines by SP.
Once SP can also be produced by inflammatory cells, a positive
feedback mechanism to the inflammatory process can be estab-
lished through this tachykinin activity. The stimulation of
human macrophages and polymorphonuclear cells by SP leads
to reactive oxygen species (ROS) production and to interleukins
and myeloperoxydase release [7–11]. These phenomena are
more evident during asthma attacks with epithelial damage [12,
13]. To minimize the damage of oxidative products, cells are
equipped with an extensive repertoire of antioxidant enzymes,
like the superoxide dismutase (SDO). If a reduction of the an-
tioxidative capacity occurs, disturbances in the oxidant/antioxi-
dant imbalance can emerge [14]. 
Several enzymes are involved in the metabolism of SP, in-
cluding neutral endopeptidase (NEP), angiotensin-converting
enzyme (ACE), and dipeptidyl aminopeptide IV (DPPIV) [1,
15]. The T-cell activation antigen CD26 is recognized as the cel-
lular marker of DPPIV, a membrane peptidase. DPPIV is a mul-
tifunctional molecule which, beside enzymatic activity, exhibits
several important functions: It can act as an adhesive molecule
by binding fibronectin, it can serve as a receptor for other en-
zymes, such as adenosine deaminase (ADA), it is the functional
receiver of collagen, and it can act as a costimulatory molecule
transducing the signal through CD3 on T lymphocytes. CD26
participates in cellular signalling due to its close association to
membrane-linked protein-tyrosine phosphatase CD45, identi-
fied as the protein of surface of larger expression in the
hematopoietic nuclear cells, resulting in the modulation of cel-
lular proliferation [16]. CD26/DPPIV is highly expressed in a
great variety of cells but in blood cells it is detected almost ex-
clusively in activated T lymphocytes [17–21].
The aim of the present study was to analyze the behaviour
of serum SP in long-lasting asthma, considering its role as an
inflammatory and bronchoconstriction inductor, evaluating
lung function parameters and establishing comparisons with SP
values found in a control population of the same age. It was
also decided to analyze the TAS and SOD production in the
same population, as well as CD26/DPPIV, considering its role
in cellular activation and modulation of the immunoinflamma-
tory response.
Methods
Subjects
A group of 105 nonsmoking elderly individuals (> 65 years,
range 65–94 years) was selected after informed oral consent.
Baseline screening data of 64 patients with mild persistent
asthma were used in this evaluation. All patients had a history of
intermittent chest tightness, wheezing or shortness of breath for
at least 30 years prior to participation in the study consistent
with the diagnosis of asthma according to the Global Initiative
for Asthma (GINA). All subjects had asthma, controlled by
using 250–500µg of beclometasone dipropionate daily and
short-acting β2-agonists as needed. All other antiasthmatic
drugs were withdrawn at least 4 weeks prior to the study.
The control group included 41 individuals. 
None of the participants had any respiratory infection in the
month previous to the study. No other clinically relevant dis-
eases were reported. Table 1 shows the characteristics of the in-
dividuals in both groups group. Sex distribution and age were
similar in the two groups studied. Cancer, autoimmunity, infec-
tion, diabetes, heart failure, renal failure, chronic hepatic, or re-
cent exposure the environmental risk factors were considered
exclusion criteria.
Diagnosis Tests
All subjects were submitted to skin prick tests to the follow-
ing 20 common aeroallergens (ALK-ABELLO; 1mm Prick
Lancetter-tames Hollister Stier): Dermatophagoides pteronyssi-
nus, Dermatophagoides farinae, Lepidoglyphus destructor, Ty-
rophagus putrescenciae, Cladosporium herbarum, Alternaria
tenuis, Blatella germanica, cat, dog, Dactylis glomerata,
Phleum pratense, Poa pratensis, Plantago lanceolata, Tarax-
acum officinale, Parietaria judaica, Artemisia vulgaris,
Chenopodium album, Platanus, Quercus suber and Olea eu-
ropaea. Histamine dihydrochloride was used as a control posi-
tive (10mg/ml) and saline solution as negative control.
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All patients were observed by a physician and performed a
spirometric test using the same equipment (Vitalograph Com-
pact) at least 6 h after the last dose of any bronchodilator. Pre-
dicted values were measured according to Knudson and col-
leagues [22]. Their spirometric performances were assessed by
means of a computerized program according to ATS’94 criteria.
The approval for analysis was determined using ATS’94 criteria;
accuracy was achieved if, within the same evaluation, three
curves were acceptable and reproducible.
The 41 control subjects and the 64 asthmatic subjects volun-
tarily agreed to provide blood samples; 30–50 ml of peripheral
blood was withdrawn from the vein of the forearm.
SP was measured in serum samples by a competitive en-
zyme immunoassay (R&D Systems, Minneapolis, MN, USA).
Within 5 min of collection approximately 500 KIU/ml of Apro-
tinin were added to all samples in order to avoid protein degra-
dation. The absorbance was read at 405 nm with a wavelength
correction set between 570 nm and 590 nm in a microplate
reader (Behring ELISA Processor II, Dade Behring, Lieder-
bach, Germany), the intensity of the color being inversely pro-
portional to the concentration of SP in the sample.
Plasma was obtained to evaluate total antioxidant status
(TAS) using Randox reagents according to methods that analyze
the inhibitory capacity of 2,2’-azino-di-3-ethylbenzotazolina
sulfonate syntheses. Superoxide dismutase enzymatic (SOD)
erythrocyte was evaluated by McCord and Fridovich/Flohé and
Ötting methods [23, 24].
Peripheral blood cells were stained with monoclonal anti-
bodies anti-CD26 phycoerythrin (PE) (Immunotech, Marseille,
France), and anti-CD3 phycoerythrin cyanine 5 (PECy5) (Dako,
Denmark) used as per the manufacturer’s specifications. Flow
Cytometry (FACS) data were collected on a FACS Calibur (BD
Biosciences, San José, CA, USA) and analyzed using Paint-a-
gate (BD Biosciences, San José, CA, USA) software.
Serum DPPIV activity was measured by a fluorimetric assay
previously described by Scharpe and colleagues [25]. DPPIV
catalyses the cleavage of the fluorogenic substrate Gly-Pro-4-Me-
Table 1
patient Characteristics
Population Number Male/Female Mean age (years) Age range
Control 41 12/29 79±7 65–94
Asthmatics 64 21/43 72±5 65–83
Table 2
Substance P Expression
Population SP (pg/ml)** Mean value SP (pg/ml) – Median
Control 39.5±41.7 17.97
Asthmatics 116.2±138.9 49.02
*Non-parametric test of Mann-Whitney [author, please check: no * in table]
** Statistical significance, p = .009
Table 3
TAS and SOD Expression
Population TAS(pl) mM*/** TAS(pl) SOD(gv) U/gHb*/** SOD(gv) U/gHb
Mean value Median Mean value Median
Control 0.91±0.10 0.93 822.9±179.5 826.20
Asthmatics 0.85±0.13 0.85 588.1±156.1 562.90
* t parametric test
** Statistical significance, p =.000
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2-NA, releasing a highly fluorescent molecule: 4-Me-2-NA. Sub-
strate, Gly-Pro-4-Me-2-NA was purchased from Sigma-Aldrich,
St. Louis, MO, USA. Standard solution, 4-Me-2-NA was ac-
quired from Bachem Feinchemikalien AG, Budendorf, Switzer-
land. The stock solution is 50mmol/L 4-Me-2-NA in DMSO. Flu-
orescence was measured with a JASCO FP-777 spectrofluorime-
ter, with a quartz cell, at 340 nm of excitation and at 425 nm of
the emission wavelengths. Serum DPPIV activity has been ex-
pressed in units/liter (U/L). One unit (U) of DPPIV activity was
defined as the enzyme activity that produced 1 µmol of 4-Me-2-
NA in 1 min under the reaction conditions.
Statistical calculations were performed using the SPSS 12.0
software package. The Kolmogorov-Smirnov test was used to
check if variables were normally distributed. For those who had
a normal distribution, the parametric t test for two independent
parameters was used. Variables that were not distributed nor-
mally were evaluated using the Mann-Whitney nonparametric
test. P values less than 0,05 were considered significant. Statis-
tical comparisons were done between the two groups, controls
and asthmatics. If scientifically relevant, comparisons between
allergic and nonallergic perticipants were also done.
Results
Among asthmatic individuals, 42 subjects (65.6%) present-
ed positive skin prick tests to common aeroallergens. Seventy
percent of the patients were sensitized to house dust mites and
most of them were polysensitized. As no significant differences
were observed between allergic and nonallergic groups when
biological parameters were analyzed, the asthmatic patients
were evaluated as a group. Asthmatic patients demonstrated an
increased expression of SP compared to normal control subjects
(p = .009) (see Table 2 and Figure 1) and a decreased expression
of TAS and SOD (see Table 3 and Figure 2). Asthmatic patients
also demonstrated an increased expression of DPPIV compared
to normal control subjects (p = .000) (see Table 4 and Figure 3)
and increased values of CD26 and CD3CD26 without statistical
significance (see Table 5 and Figure 4).
All patients were clinically stable and presented an average
percentage of predicted forced expiratory volume in the first
second (FEV1) of 73.6±25.3 and median expiratory flow per-
centage of predict (MEF50) of 38.8±26.7.
Discussion 
The increased value of SP presented in asthmatic patients
when compared with normal controls confirms the role of this
neurokinin in the disease. The studies were carried out in indi-
viduals older than 65 years that had had asthma symptoms for
more than 30 years. SP stimulates the smooth muscle receptors
inducing bronchoconstriction and narrowing of the airways.
When inducing neurogenic inflammation, SP increases the pro-
duction of oxygen radicals, as well as cellular activation, mainly
lymphocyte activation. The asthmatic population studied pre-
sented lower values of respiratory parameters when compared
with controls. In the asthmatic patients, the percentage of forced
expiratory volume in the first second (FEV1) observed was
negatively correlated with SP (Pearson correlation = -0.272, 
p = 0.05), which suggests that the increase of SP in these
patients may have a decisive role in the functional obstructive
pattern observed.
The production of oxygen radicals enhances the bronchial
inflammation of asthmatic patients and antioxidant defences are
considered the main mechanisms of negative control in this
process. The release of oxygen radicals is induced by SP which
can be significantly increased in asthma. The significant de-
crease of TAS and SOD observed may affect tissue repair in
asthma. During the ageing process, the antioxidant defences
Table 4
DPPIV Expression
Population DPPIV(U/L)*/ ** – DPPIV(U/L) – 
Mean value Median
Control 58.6±14.3 60.88
Asthmatics 69.7±15.2 70.25
* t parametric test
** Statistical significance, p = .000
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Figure 1. Substance P Expression.
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tend to decrease, which is associated with susceptibility to
chronic inflammatory diseases. The reduction of tachykinin re-
ceptors or decrease in the neurogenic answer to mediators such
as acetylcholine in the elderly, reported in some studies, does
not appear to limit this neurogenic inflammation [26, 27]. 
The increase in CD26/DPPIV values in the asthmatic pa-
tients when compared to the control population can result from
cell activation during the inflammatory process. Considering
that DPPIV can be involved in the catabolism of peptides impli-
cated in asthma pathology, the significant increase of serum
DPPIV observed probably represents a negative control to limit
enzymatic activity of SP and other proteases.
The enzymatic activities involved in the degradation of other
tachykinins, such as the conversion enzyme of the angiotensin
and the neutral endopeptidase, probably have a modulating role
in the neurogenic inflammation of the airways. It was accepted
that increased activity of neuropeptides or the reduction of their
catabolism was associated with an increase in vascular perme-
ability of the nasal mucous membrane with plasma transuda-
tion and inflammatory cell infiltration [28]. DPPIV seems to
maintain low values up to 65 years of age [29, 21], while indi-
viduals over 65 years of age can present a sustained higher ex-
pression of this peptidase [17]. 
The task of the inflammatory cells in neurogenic inflam-
mation is difficult to define and one of the main problems lies
in the changes of these cells’ receptor expression during the
different phases of their maturation and traffic from their ori-
gin to the inflammatory injury [1]. SP can work as an inductor
of mediator release from inflammatory tissues, creating a pos-
itive mechanism to continue the inflammatory process and the
potential immune modulating ability. This explains the para-
dox observed between the relatively low concentration of SP
in the nerve endings of the airways and its considerable pres-
ence in sputum and in bronchoalveolar lavage fluid. This is
probably a result of local production of SP by inflammatory
cells [30] which confers on this neuropeptide a crucial respon-
sibility in airway obstruction. The local microenvironment in
the different tissues seems to be an important feature for the
development of SP activities. In fact, it was demonstrated that
SP injection into healthy skin does not induce neutrophil infil-
tration, while the same procedure in inflamed skin causes neu-
trophil accumulation [7]. It is believed that this activity is not
specific to the skin.
Bronchoalveolar lavage fluid and sputum samples collected
from asthmatics after antigen challenge showed an increase in
SP. The amount of SP determined in lung tissue was reduced in
asthmatics and in patients who died in status asthmaticus, thus
 TAS     SOD 
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Figure 2. Total antioxidant
activity in serum and superoxide
dismutase expression.
Table 5
CD26 and CD3CD26 Values
Population CD3/CD26*/** CD3/CD26 CD26*/** CD26
Mean value Median Mean value Median
Control 36.2±10.6 35.70 39.4±11.4 37.55
Asthmatics 39.8±8.9 40.40 41.9±10.2 43.10
* t-parametric test
**No statistical significance
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reflecting exaggerated release of SP in the airways of asthmatics
and the consequent depletion in the lung parenchyma [1].
Within the airways, immunoreactive tachykinins are present
in nerve fibers which are localized to submucosal glands, air-
way smooth muscle, bronchial vessels and airway epithelium. It
was also demonstrated that after the elimination of cholinergic
and adrenergic neural pathways, the nonadrenergic, noncholin-
ergic (NANC) neurogenic secretory response remained, com-
prising approximately 40% of the total secretory response,
which confirms the important role that SP assumes in respirato-
ry pathology [10]. 
The sensitization to common aeroallergens observed in
some asthmatic patients did not introduce significant differ-
ences in the biological markers that were analyzed. However,
according to other authors, airway narrowing and the level of
bronchial responsiveness are associated with atopy in adults 
> 65 years of age and should not be neglected [31]. In spite of
the tendency of immunoglobulin E (IgE) values to decrease
with age, IgE-mediated allergy can be present in 75% of elderly
asthmatics [32].
The human respiratory tract epithelium can produce antioxi-
dant species as a defence mechanism since they are consumed
to face different triggers [33].The reduction of the values of su-
peroxide dismutase has been referred to in asthma and in other
chronic diseases and consequently the balance between the ox-
idative challenge and antioxidative defence is affected. Some
asthmatic patients seem to have only a SOD reduction [34, 35].
Consistent with these observations, higher levels of ROS have
already been reported in exhaled air condensates of asthmatics
which are directly correlated with the severity of the disease [8,
12, 36]. These changes may occur associated with nutrient in-
take disturbances and chronic inflammatory disabilities. Some
studies highlight a potential role of antagonists of NK-1 and of
the ROS deplectors in the therapy of asthma [12]. 
In conclusion, the results confirm the role of SP in bronchial
asthma and help to clarify the network of interactions connected
with this disease. It should be emphasized that these immunoin-
flammatory changes are present in the elderly population with
breathing pathology. The data suggest that additional therapeu-
tic approach to this pathology should be developed.
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